An in vivo and in vitro evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine: an inhibitor of human lymphoblast purine nucleoside phosphorylase.
D000248:Adenosine Kinase / Q000172:deficiency; D002460:Cell Line; D005573:Formycins / Q000494:pharmacology; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D007288:Inosine / Q000378:metabolism; D008214:Lymphocytes / Q000201:enzymology*; D010430:Pentosyltransferases / Q000037:antagonists & inhibitors*; D011683:Purine-Nucleoside Phosphorylase / Q000037:antagonists & inhibitors*; D012254:Ribavirin / Q000031:analogs & derivatives / Q000494:pharmacology*; D012263:Ribonucleosides / Q000494:pharmacology*
D005573:Formycins; D012263:Ribonucleosides; D012254:Ribavirin; D007288:Inosine; D007168:IMP Dehydrogenase; D010430:Pentosyltransferases; D011683:Purine-Nucleoside Phosphorylase; D007041:Hypoxanthine Phosphoribosyltransferase; D000248:Adenosine Kinase; C026956:taribavirin